Skip to main content

Table 1 Inclusion and exclusion criteria for the study

From: Randomized, placebo controlled, double blinded pilot superiority phase 2 trial to evaluate the effect of curcumin in moderate to severe asthmatics

Inclusion criteria Exclusion criteria
Male or female, aged 18 and older
Physician diagnosed moderate to severe asthma: (GINA 2018)
Stable asthma that requires ICS/LABA and/or an additional controller agent (i.e. LTRA, LAMA)
Ability to take oral medication and be willing to adhere to the regimen
Ability to speak and read English
If female and sexually active, should use effective forms of birth control
Current use of turmeric (curcumin) or use within the last 7 days
Current use of biologic therapy/immunotherapy/ or bronchothermoplasty
Pregnancy or lactation
Known allergic reactions to components of turmeric (curcumin)
Current use of anticoagulants, and history of coagulopathy or liver disease
INR greater than 2.0, PTT greater than 45.0 s
  1. GINA Global initiative for asthma, ICS inhaled corticosteroids, LABA long-acting beta agonist, LTRA leukotriene receptor antagonist, LAMA long acting muscarinic, INR international normalized ratio, PTT partial thromboplastin time